## **Senator Girod**

## SUBCOMMITTEE RECOMMENDATION

## HB 3273 Relating to drugs

HB 3273 requires certain specified drug manufacturers to use program operators to participate in a drug take-back program. Covered manufacturers must pay all costs associated with participating in a drug take-back program. With passage of the measure, the Department of Environmental Quality and the Oregon Board of Pharmacy will be responsible for ensuring compliance with the drug take-back program. Program operators must submit program plans to the Department of Environmental Quality for approval.

DEQ estimates the fiscal impact of administering the drug take-back program to be \$258,202 Other Funds and 2 positions (0.94 FTE) for the 2019-21 biennium, and \$144,586 Other Funds and 1 position (0.50 FTE) for the 2021-23 biennium. The measure authorizes DEQ to assess fees to pay the costs of administering the program.

The Capital Construction Subcommittee recommends HB 3273 be amended by the -A15 and be reported out do pass, as amended.